<DOC>
	<DOCNO>NCT02302079</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety ASP8232 subject diabetic macular edema ( DME ) . This study evaluate percent change baseline excess central subfield thickness ( CST ) study eye assess spectral domain-optical coherence Tomography ( SD-OCT ) ASP8232 monotherapy Month 3 .</brief_summary>
	<brief_title>A Study Evaluate ASP8232 Reducing Central Retinal Thickness Subjects With Diabetic Macular Edema ( DME )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Subject must document diagnosis type 1 type 2 diabetes mellitus glycosylated hemoglobin A1c ( HbA1c ) ≤ 12.0 % Screening Subject definite retinal thickening due diffuse diabetic macular edema ( DME ) involve central macula base evaluate investigator 's clinical evaluation demonstrate spectral domainoptical coherence tomography ( SDOCT ) Subject central subfield thickness ( CST ) least 375 μm SDOCT presence intraretinal and/or subretinal fluid screen visit randomization visit Subject early treatment diabetic retinopathy study ( ETDRS ) best correct visual acuity ( BCVA ) letter score ≤ 73 ( Snellen 20/40 ) ≥ 24 ( Snellen 20/320 ) screen visit Subject 's study eye macular edema consider due cause DME Subject 's study eye decrease BCVA due cause DME likely decrease BCVA 3 line Subject 's study eye significant macular ischemia show angiography Subject 's study eye ocular disease may cause substantial reduction BCVA Subject active periocular ocular infection Subject 's study eye history noninfectious uveitis Subject 's study eye high myopia ( 8 diopter correction ) Subject 's study eye history prior par plana vitrectomy Subject 's study eye history ocular surgery within 3 month prior Day 1 Subject 's study eye history YAG capsulotomy within 3 month prior Day 1 Subject 's study eye history panretinal scatter photocoagulation ( PRP ) focal laser within 3 month prior Day 1 anticipate need PRP course study Week 12 visit Subject 's study eye history prior IVT , subtenon , periocular , nonsustained release , steroid therapy within 3 month prior Day 1 Subject 's study eye history intravitreal sustain release dexamethasone therapy within 6 month prior Day 1 . Subject 's study eye history intravitreal sustain release fluocinolone within 3 year prior Day 1 . Subject 's study eye history prior treatment DME IVT antivascular endothelial growth factor ( VEGF ) treatment within 8 week prior Day 1 Subject history prior treatment ( previously list ) approve treatment label DME within 1 year prior Day 1 Subject 's study eye highrisk proliferative diabetic retinopathy ( PDR ) Subject uncontrolled glaucoma Subject medium clarity , papillary constriction ( i.e. , senile miosis ) , subject lack cooperation would interfere study procedure , evaluation interpretation data</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>ASP8232</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>ranibizumab</keyword>
	<keyword>Diabetic Macular Edema</keyword>
</DOC>